148 related articles for article (PubMed ID: 38833157)
1. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
Kobayashi T; Iwama S; Yamagami A; Izuchi T; Suzuki K; Otake K; Yasuda Y; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Nishio N; Mori S; Shimokata T; Sano T; Niimi K; Yoshikawa N; Akamatsu S; Ando Y; Akiyama M; Sone M; Ishii M; Arima H
Cancer Immunol Immunother; 2024 Jun; 73(8):146. PubMed ID: 38833157
[TBL] [Abstract][Full Text] [Related]
2. Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline.
Iwama S; Kobayashi T; Yasuda Y; Okuji T; Ito M; Ando M; Zhou X; Yamagami A; Onoue T; Kawaguchi Y; Miyata T; Sugiyama M; Takagi H; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Wakahara K; Yokota K; Kato M; Nishio N; Tanaka C; Miyata K; Ogura A; Ito T; Sawada T; Shimokata T; Niimi K; Ohka F; Ishigami M; Gotoh M; Hashimoto N; Saito R; Kiyoi H; Kajiyama H; Ando Y; Hibi H; Sone M; Akiyama M; Kodera Y; Arima H
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1620-e1630. PubMed ID: 34791304
[TBL] [Abstract][Full Text] [Related]
3. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade.
Kobayashi T; Iwama S; Yamagami A; Yasuda Y; Okuji T; Ito M; Zhou X; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Ito T; Kikumori T; Inoue M; Ando Y; Masuda N; Kawashima H; Hashimoto N; Arima H
J Clin Endocrinol Metab; 2022 Sep; 107(10):e4115-e4123. PubMed ID: 35918067
[TBL] [Abstract][Full Text] [Related]
4. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
5. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
7. Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline.
Zhou X; Iwama S; Kobayashi T; Ando M; Arima H
J Clin Endocrinol Metab; 2023 Sep; 108(10):e1056-e1062. PubMed ID: 37084392
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
Yoon JH; Hong AR; Kim HK; Kang HC
Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
[TBL] [Abstract][Full Text] [Related]
12. Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade.
Yamagami A; Iwama S; Kobayashi T; Zhou X; Yasuda Y; Okuji T; Ito M; Izuchi T; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Arima H
Endocr J; 2024 May; 71(5):515-526. PubMed ID: 38599854
[TBL] [Abstract][Full Text] [Related]
13. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):445-453. PubMed ID: 29652597
[TBL] [Abstract][Full Text] [Related]
14. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
Schoenfeld AJ; Arbour KC; Rizvi H; Iqbal AN; Gadgeel SM; Girshman J; Kris MG; Riely GJ; Yu HA; Hellmann MD
Ann Oncol; 2019 May; 30(5):839-844. PubMed ID: 30847464
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
17. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.
Drui D; Illouz F; Do Cao C; Caron P
Ann Endocrinol (Paris); 2018 Oct; 79(5):569-573. PubMed ID: 30126626
[TBL] [Abstract][Full Text] [Related]
18. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Schwarz M; Nogai H; Grille P; Westermann J; Plöckinger U; Braun D; Schweizer U; Arnold R; Dörken B; le Coutre P
Thyroid; 2010 Nov; 20(11):1209-14. PubMed ID: 20929406
[TBL] [Abstract][Full Text] [Related]
19. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
